Paul Alloway
Net worth: 44 236 $ as of 2024-03-30
Profile
Paul G.
Alloway worked as Vice President & Senior Counsel at DRI Capital, Inc. He also served as Secretary & Head-Legal at Foghorn Therapeutics, Inc. In 2022-2023, he held the position of Secretary & Chief Legal Officer at Homology Medicines, Inc. Dr. Alloway obtained a doctorate degree from Dartmouth College.
He completed his undergraduate studies at the University of Toronto and pursued his graduate degree at Suffolk University Law School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
0.02% | 2024-03-24 | 2,596 ( 0.02% ) | 44 236 $ | 2024-03-30 |
Former positions of Paul Alloway
Companies | Position | End |
---|---|---|
FOGHORN THERAPEUTICS INC. | General Counsel | - |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | General Counsel | - |
Q32 BIO INC. | Chief Executive Officer | - |
Training of Paul Alloway
Dartmouth College | Doctorate Degree |
University of Toronto | Undergraduate Degree |
Suffolk University Law School | Graduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
FOGHORN THERAPEUTICS INC. | Health Technology |
Private companies | 2 |
---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
- Stock Market
- Insiders
- Paul Alloway